Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Alnylam To Work With The Medicines Co.
by Ann M. Thayer
February 11, 2013
| A version of this story appeared in
Volume 91, Issue 6
The Medicines Co. and Alnylam Pharmaceuticals will collaborate on Alnylam’s ALN-PCS RNAi therapeutic program for treating hypercholesterolemia. ALN-PCS inhibitors target the proprotein convertase subtilisin/kexin type 9 gene involved in the metabolism of low-density lipoprotein, or “bad,” cholesterol. TMC will pay Alnylam $25 million up front and milestone payments of up to $180 million. Alnylam’s ALN-PCS02 candidate has completed a Phase I clinical trial; ALN-PCSsc is in preclinical development. TMC will lead development from Phase II through commercialization.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter